Hyper-cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus rituximab (hyper-CVAD-R) can prevent central nervous system (CNS) relapse in patients with Burkitt leukemia/lymphoma (BL) or high-grade B-cell lymphoma (HGBL), according to a study published in Blood Advances. The retrospective study included 79 patients with newly diagnosed BL (n=54) or HGBL (n=25) who were treated...
Latest News
NEW YORK — In recent decades, there have been periodic reports of a worldwide decline in sperm count and quality. Male infertility has ostensibly been on the rise, accompanied by increases in testicular cancer and hypospadias — a congenital defect in which the opening of the urethra is on the...
SHANGHAI and GAITHERSBURG, Md. – I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in an abbreviated combination clinical study (NCT04202003) of lemzoparlimab (also known as TJC4) with azacitidine (AZA) in patients with newly...
GENOA, Italy — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the first subject was treated with IAMA-6, an orally administered small molecule therapeutic targeting NKCC1. IAMA-6, IAMA’s lead program, is being evaluated for...
SHANGHAI and NANJING, China and SAN JOSE, Calif., — IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for Equecabtagene Autoleucel (IASO Bio R&D...
SHANGHAI, NANJING, China and SAN JOSE, Calif. — IASO Biotechnology, a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercialising innovative cell therapy and antibody products, is pleased to announce that the Investigational New Drug (IND) application for its BCMA CAR-T (Equecabtagene Autoleucel) has been approved by the U.S. Food...
SHANGHAI, NANJING, China and PLEASANTON, Calif. — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month long-term follow-up data from the FUMANBA-1 study of its independently developed fully human anti-BCMA CAR-T cell therapy Fucaso (Equecabtagene Autoleucel, Eque-cel), for the treatment...
Ibrutinib improved event-free survival (EFS) when compared with placebo in patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL), according to phase 3 trial results published in Blood. However, because overall survival (OS) data from this trial are pending, researchers concluded that they cannot recommend ibrutinib over a “watch and wait” approach...
Daejeon, South Korea – The human brain’s adaptability to internal and external changes, known as neural plasticity, forms the foundation for understanding cognitive functions like memory and learning, as well as various neurological disorders. New research conducted by a team led by Dr. PARK Joo Min of the Center for...
New York, NY — The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million from The Leona M. and Harry B. Helmsley Charitable Trust to support an innovative research project aimed at understanding the early stages of Crohn’s disease before noticeable symptoms...